Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 26.7% during trading on Friday . The company traded as high as C$0.10 and last traded at C$0.10. 815,880 shares changed hands during trading, an increase of 115% from the average session volume of 380,109 shares. The stock had previously closed at C$0.08.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a market cap of C$19.58 million, a price-to-earnings ratio of -2.97 and a beta of 1.39. The company’s 50-day simple moving average is C$0.11 and its 200-day simple moving average is C$0.12.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- What is the NASDAQ Stock Exchange?
- DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?
- How to Calculate Inflation Rate
- Engines to AI: Cummins’ Surprising Growth Driver
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Smaller Industrials Names Seeing Surging Growth: Here’s Why
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
